Microdosing Psilocybin for Chronic Pain: Cluster Headache and Migraine Data

Psilocybin for Headache & Pain

18.4 → 9.8 cluster headache attacks per week

A 2024 blinded extension trial found that a repeated psilocybin pulse regimen cut cluster headache attack frequency nearly in half over 8 weeks.

Schindler et al., Journal of Neurological Sciences, 2024

1.65 vs 0.15

migraine days reduced per week: psilocybin vs placebo (Schindler 2021)

d=1.25

effect size in chronic cluster headache, a large clinical signal (Schindler 2022)

76.2%

of psilocybin pain studies rated low or very low quality; this Schindler work is the best we have (Jevotovsky 2025)

Schindler et al., Journal of Neurological Sciences, 2024

View as image ↗

Cluster headache has been called the suicide headache. The name is clinical, not metaphorical: it refers to the suicidal ideation that frequently accompanies what researchers consistently rate among the most painful conditions known to humans. Attacks can run to 8 or more per day in chronic cases. They are severe enough that patients describe them as preferable to nothing only because the alternative is unbearable. Conventional prophylactics, including verapamil and lithium, fail a substantial portion of patients or produce side effects that make them impractical.

For this reason, cluster headache patients have been experimenting with psilocybin outside of clinical settings since at least the early 2000s. The psilocybin microdosing cluster headache migraine data that researchers have now collected through controlled trials spans four publications from a single Yale lab between 2021 and 2026. No other research group has built this kind of systematic evidence in either headache condition.

This article presents that data in full, with the specific numbers that let you evaluate the evidence yourself. For the broader picture of psilocybin microdosing and the complete guide to psilocybin microdosing explains the fundamentals of dose and practice.

The Evidence Problem: Why 76% of Pain Studies Don't Answer the Question

Before the Schindler data, the broader research base for psilocybin and pain was thin. Jevotovsky and colleagues published a systematic review in 2025 that examined 28 studies on psilocybin and chronic neuropathic pain.^[6] Their finding: 76.2% were low or very low quality. The field was built primarily on case reports, surveys, and observational studies, with almost no randomized controlled evidence.

This context matters for reading the Schindler trials. When 76% of available studies are low quality, even imperfect controlled data represents a significant step forward. The Schindler series is, by a wide margin, the highest-quality evidence that exists for psilocybin in any headache condition. Understanding where that evidence sits in the quality hierarchy is essential for interpreting what it can and cannot tell us.

For the mechanism context, the research suggests at least three pathways through which psilocybin might reduce chronic pain: 5-HT2A receptor agonism at spinal and central levels (reducing pain signal transmission), neuroplasticity via BDNF signaling, and anti-inflammatory effects. The complete mechanistic picture is covered in Can Sub-Perceptual Psilocybin Reduce Pain? Mechanisms, which examines the pharmacological basis in full.

The Schindler Progression: Five Years of Yale Trials in One View

Evan Schindler's group at Yale has run a systematic research program through the same dose protocol, building each trial on the previous one. Here is what four publications found:

All trials used a psilocybin pulse regimen: three low-to-moderate doses spaced 5 days apart. This is not a traditional microdose. At 10mg per 70kg of body weight, participants typically experienced mild psychoactive effects. The critical finding across studies is that the headache benefit was independent of how intense those effects were. That independence is the bridge to the microdosing hypothesis.

Schindler 2021: Migraine Frequency Drops 11 Times Faster Than Placebo

The 2021 migraine trial was the first controlled study of psilocybin for migraine prevention, and its headline finding is striking.^[1]

Participants received a single psilocybin dose or placebo in a crossover design, then tracked their migraines over two weeks. The psilocybin group saw their migraine frequency fall by 1.65 days per week. The placebo group's frequency fell by 0.15 days per week. That is an 11-fold difference in the rate of improvement.

The trial also found reductions in pain severity, functional impairment, and abortive medication use. But the most scientifically important finding was a negative correlation: the magnitude of clinical benefit did not correlate with the intensity of the acute psychedelic experience. Patients who barely noticed the drug and patients who experienced strong effects both improved at similar rates. This suggests the migraine prevention mechanism operates at a different level than the psychedelic experience itself, possibly via sustained serotonergic or neuroplastic changes rather than a single perceptual event.

The implication is significant: you may not need a perceptual dose to get migraine prevention benefits from psilocybin. That is the hypothesis that subsequent research has tried to test.

Schindler 2022: Why a "Negative" Trial Still Points in One Direction

The 2022 cluster headache trial is regularly described as negative, and technically that is accurate: the primary endpoint did not reach statistical significance.^[2]

But understanding what "negative primary endpoint" actually means here requires looking at what the study was powered to detect. The trial enrolled a small number of participants. In that context, a p-value of 0.251 means the study lacked statistical power to confirm the effect it observed, not that the effect was absent. The data showed psilocybin reduced cluster attacks by 3.2 per week versus 0.03 per week for placebo. That direction is consistent and strong. The problem was the sample size.

The subgroup analysis tells the clearest story. Participants were divided into those with chronic cluster headache (attacks occurring continuously without remission periods) and those with episodic cluster headache (attacks in seasonal cycles). In the chronic subtype, the effect size was Cohen's d=1.25. In the episodic subtype, it was d=0.35.

A Cohen's d of 1.25 is considered a very large effect in clinical research. An effect that large in a small sample is what underpowered trials look like when the treatment actually works. The 2024 extension was designed precisely to follow up on what this effect size predicted.

Chronic vs. Episodic Cluster Headache: The Subtype That Responds

The distinction between chronic and episodic cluster headache matters for interpreting all the psilocybin data.

Episodic cluster headache attacks come in clusters that last weeks to months, followed by remission periods of equal or longer duration. Episodic patients have natural breaks in their attacks; placebo effects and natural remissions can be hard to distinguish from treatment effects.

Chronic cluster headache has no remission periods. Attacks are continuous, often for years. This makes chronic patients harder to treat conventionally but also makes clinical trial results easier to interpret, because there is no natural improvement cycle to confound the data.

The d=1.25 effect size in Schindler 2022 came from the chronic subtype. The patients most resistant to conventional treatment showed the strongest signal. This is the opposite of what you would expect from a placebo effect, which tends to be largest in conditions with variable natural courses.

Schindler 2024: The Extension Confirms What the Effect Size Predicted

The 2024 publication extended the cluster headache trial into a blinded phase with 10 chronic cluster headache participants.^[3]

The result confirmed what the 2022 effect size had predicted. Average attack frequency dropped from 18.4 attacks per week to 9.8 attacks per week. That is a reduction of 8.6 attacks per week, or approximately 47% fewer attacks. The effect was sustained over the 8-week follow-up period.

To put 18.4 attacks per week in context: that is 2-3 attacks per day in a condition where each attack lasts 15 minutes to 3 hours and has been described by patients as more severe than childbirth without anesthesia or kidney stones. A 50% reduction at that baseline is clinically meaningful even in a small sample.

The 2024 extension used the same pulse regimen as 2022: psilocybin at roughly 10mg/70kg across three doses spaced 5 days apart. The blinded design means participants did not know which phase they were in. The sustained effect over 8 weeks rules out simple acute drug effects as the explanation.

Schindler 2026: Single vs. Repeat Dose for Migraine Prevention

The 2026 publication addressed a question that the earlier migraine trial left open: does repeat dosing outperform a single dose?^[4]

The 2021 trial used a single dose. If migraine benefits come from sustained neuroplastic changes, a single dose might be sufficient. If they require repeated serotonergic stimulation, a pulse regimen should outperform a single dose. These are testable hypotheses.

Schindler's 2026 exploratory RCT from Yale compared single-dose psilocybin against repeat-dose psilocybin against active placebo in a three-arm design. This is the first study to directly pit these protocols against each other in migraine prevention. The results provide guidance on whether the clinical benefit scales with dosing frequency or whether a single session captures most of the effect.

Community Data: What Cluster Headache Patients Actually Report

Controlled trials provide the most reliable evidence but also exclude most of the population: small samples, strict eligibility criteria, laboratory settings. The community data adds scale and real-world context.

Henderson and colleagues reviewed clinical evidence and community-use data for psychedelics in headache disorders in 2025.^[5] In self-reported cluster headache use, 22 out of 26 users reported successfully aborting individual attacks. Among those tracking longer-term outcomes, 25 out of 48 reported that psilocybin terminated an entire cluster period, not just individual attacks.

That community-level finding, 25 of 48 patients reporting period termination, is a different kind of outcome than what the clinical trials measured. Trials measure attack frequency within a defined window. Period termination represents a shift in the underlying biology: the cluster cycle ends rather than slowing.

The mechanism distinction is relevant here. Conventional treatments for cluster headache reduce attack frequency during an active cluster period but do not reliably terminate the cluster. If psilocybin is terminating cluster periods in a significant fraction of users, that points to a different target than conventional prophylaxis.

Henderson's review also confirmed the dose-independence pattern from the Schindler trials: clinical headache benefits in community reports did not appear to depend on the perceptual intensity of the psychedelic experience.

The Broader Pain Picture: Case Reports and Population Surveys

The headache trials are the most rigorous psilocybin pain data available, but two other data sources provide useful context.

Lyes and colleagues published a case series in PAIN in 2023 describing three patients with chronic neuropathic pain, including spinal cord injury and complex regional pain syndrome, who used microdosed psilocybin.^[7] Doses ranged from 250mg to 1,000mg of dried mushroom. All three patients reported 80 to 100% pain relief without experiencing any psychedelic effects. All three reduced or eliminated opioid use. The effects lasted from 3 hours to 2 weeks depending on the patient.

These are three people, not a trial. Case series are the lowest rung of clinical evidence. What they establish is that sub-perceptual doses can produce meaningful pain relief in neuropathic conditions, which aligns with the dose-independence finding from the Schindler migraine data. For a sub-perceptual dose to relieve pain, the mechanism cannot require a psychedelic experience.

Bonnelle and colleagues' 2022 survey of 250 chronic pain patients with psychedelic experience added quantitative population-level data.^[8] On a 10-point pain relief scale, macrodoses averaged 8.25, microdoses averaged 6.51, and conventional medications including opioids averaged 5.32. Both psychedelic approaches outperformed conventional treatment. Migraine patients showed a particularly strong response to microdoses. The analgesic effect was not mediated by mood improvement: pain relief correlated with dose type, not with mood change.

For readers considering long-term pain management with any psilocybin protocol, the safety picture matters too. Microdosing and Heart Health: The 5-HT2B Valvulopathy Concern covers the cardiac risk relevant to chronic use. For the pharmacological basis of why sub-perceptual doses affect pain at all, How 5-HT2A Agonism Creates the Psychedelic Experience explains the receptor biology that distinguishes pain-relevant from experience-relevant activity.

What the Data Collectively Shows

Five years of Schindler trials at Yale have produced the strongest controlled evidence for psilocybin in any headache condition. The migraine data is more mature: a crossover RCT showing 11x faster improvement than placebo and a 2026 dosing comparison. The cluster headache data is directionally strong but small: a technically negative primary endpoint with a large effect size in the chronic subtype, confirmed by a blinded extension showing 50% attack reduction.

The consistency across the data, from controlled trials to community reports to case series, points toward a genuine pharmacological effect that does not require full psychedelic intensity to operate. The dose-independence finding is the most theoretically important result: if migraine prevention and cluster headache reduction do not correlate with psychedelic experience intensity, the mechanism is operating at a level that sub-perceptual doses can reach.

What remains unknown: optimal dosing protocols, which patients respond best, how long effects last, and whether the benefit generalizes beyond the Yale lab's specific pulse regimen. The Jevotovsky systematic review's finding that 76.2% of existing studies are low quality applies here too, even though the Schindler work sits above the rest of the field.

For a broader look at how microdosing affects chronic pain beyond headache, Microdosing Psilocybin for Chronic Pain: Emerging Research covers the neuropathic and general pain evidence. For the direct comparison of what full-dose versus sub-perceptual psilocybin achieves in pain settings, Microdosing vs. Full-Dose Psilocybin for Pain Management maps the Bonnelle data and trial evidence against each other. And for the headache-focused community evidence and clinical considerations, Microdosing for Migraines and Cluster Headaches takes the more accessible approach to the same underlying research.

The Bottom Line

The best available clinical evidence for psilocybin in headache conditions comes from four Yale trials by Schindler and colleagues spanning 2021 to 2026. The migraine data shows an 11-fold advantage over placebo in attack frequency reduction. The cluster headache data showed a large effect size in the chronic subtype (d=1.25) in an underpowered trial, confirmed by a 2024 blinded extension showing 50% attack reduction. The consistent finding across all studies: benefit does not correlate with psychedelic experience intensity, suggesting sub-perceptual doses may achieve similar clinical results. Outside the trials, population survey data shows microdoses outperform conventional medications including opioids on self-reported pain relief.

Frequently Asked Questions

What does research show about psilocybin for cluster headaches?

The most rigorous evidence comes from Schindler's Yale trials. The 2022 RCT missed its primary endpoint due to small sample size (p=0.251) but showed a large effect size in chronic cluster headache patients (Cohen's d=1.25). A 2024 blinded extension of that trial found that a repeated psilocybin pulse regimen reduced attack frequency from 18.4 to 9.8 attacks per week in 10 chronic cluster patients over 8 weeks. Community data from Henderson 2025 found 22 of 26 users reported aborting individual attacks, and 25 of 48 reported ending an entire cluster period.

How many cluster headache attacks does psilocybin reduce?

In the most controlled data available, the Schindler 2024 extension trial found that a three-dose psilocybin pulse regimen reduced chronic cluster headache attacks from an average of 18.4 per week to 9.8 per week, approximately a 47% reduction sustained over 8 weeks in 10 patients. The 2022 trial data that preceded it showed a reduction of 3.2 attacks per week versus 0.03 for placebo, though this difference was not statistically significant in the small sample.

Is psilocybin more effective for chronic or episodic cluster headache?

The controlled trial data suggests chronic cluster headache responds more strongly. Schindler's 2022 RCT found a Cohen's d effect size of 1.25 in the chronic subtype versus 0.35 in the episodic subtype. Chronic cluster patients have no natural remission periods, which makes a 1.25 effect size harder to attribute to placebo or natural variation. The 2024 extension that confirmed the 50% attack reduction also enrolled only chronic cluster patients.

Can psilocybin prevent migraines?

Schindler's 2021 crossover RCT found that a single psilocybin dose reduced migraine frequency by 1.65 days per week compared to 0.15 days per week for placebo over a 2-week follow-up. The trial also found reductions in pain severity and abortive medication use. The benefit did not correlate with how intense the psychedelic experience was, which suggests the prevention mechanism operates independently of the acute drug effects. A 2026 trial from the same lab compared single-dose versus repeat-dose protocols for migraine prevention.

What is the psilocybin cluster headache trial?

The primary cluster headache trial is Schindler et al. 2022, a randomized double-blind placebo-controlled trial of a patient-informed low-dose psilocybin pulse regimen (three doses of approximately 10mg/70kg, spaced 5 days apart) versus placebo in cluster headache patients. The trial was published in Headache. Its primary endpoint did not reach significance in the full sample, but showed a large effect in the chronic subtype. A 2024 blinded extension by the same Yale group confirmed the chronic cluster finding with a 50% reduction in attack frequency over 8 weeks.

Sources & References

1. 1RTHM-00716·Schindler, Emmanuelle A D et al. (2021). “Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin..” Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.Study breakdown →PubMed →↩
2. 2RTHM-00794·Schindler, Emmanuelle A D et al. (2022). “Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial..” Headache.Study breakdown →PubMed →↩
3. 3RTHM-01982·Schindler, Emmanuelle A D et al. (2024). “Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial..” Journal of the neurological sciences.Study breakdown →PubMed →↩
4. 4RTHM-00963·Schindler, Emmanuelle A D et al. (2026). “Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial..” Headache.Study breakdown →PubMed →↩
5. 5RTHM-00927·Henderson, Isabella et al. (2025). “Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights..” Current pain and headache reports.Study breakdown →PubMed →↩
6. 6RTHM-02100·Jevotovsky, David S et al. (2025). “Psilocybin and chronic neuropathic pain: a systematic review..” Regional anesthesia and pain medicine.Study breakdown →PubMed →↩
7. 7RTHM-01742·Lyes, Matthew et al. (2023). “Microdosing psilocybin for chronic pain: a case series..” Pain.Study breakdown →PubMed →↩
8. 8RTHM-01489·Bonnelle, Valerie et al. (2022). “Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey..” British journal of pain.Study breakdown →PubMed →↩